TYRATyra Biosciences, IncSigning up patients
Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma
Low Grade Upper Tract Urothelial Carcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 285 (planned)
- Started
- Dec 22, 2025
- Main results expected
- Oct 2030
- Fully finished
- Nov 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
To assess the efficacy of Dabogratinib in LG UTUC FGFR3+ participants (proportion of participants with a CR within 6 months out of all LG UTUC FGFR3+ participants)
Measured over: within 6 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07265947 · record last updated 2026-11-02 · checked 2026-11-09 15:47 UTC